Mark W Dewhirst

This inventor holds 31 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Cancer Treatment Technologies. Top assignees: Duke University, Immunolight, LLC, Apex Bioscience, Inc.. Active years: 1988-2024.

USPTO Granted Patents = 31 (Patent Applications = 10)

% Patents Active = 67.7

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 4.4

ph-index = 9

Forward Citations = 228(Granted Patents)

Location History:

Durham, NC (US) (1988 - 2023)
Chapel Hill, NC (US) (1996 - 2023)

Company Filing History:

Apex Bioscience, Inc.

patents

4. 4 out of 1,488

North Carolina State University

Yeda Research and Develpment & Co. Ltd

patents

7. 1 out of 1

Creative Scientist, Inc.

patent

where one patent can have more than one assignee

Years Active: 1988-2024

Loading Chart...

Areas of Expertise:

Radiotherapy

Cancer Therapy

Biomarkers

Phosphors

Scintillators

MRI Imaging

Tumor Imaging

Oxygenation Agents

Therapeutic Agents

Light Activation

Drug Distribution

Hyperthermia

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12171769 - Methods, compositions, and kits for treating and/or preventing a side effect associated with radiation and/or chemotherapy exposure (2024-12-24),

2. 11786595 - Methods for radiotherapy to trigger light activation drugs (2023-10-17),

3. 11571587 - Method for treating a disease, disorder, or condition using inhalation to administer an activatable pharmaceutical agent, an energy modulation agent, or both (2023-02-07),

4. 11285162 - Methods, compositions, and kits for treating and/or preventing a side effect associated with radiation and/or chemotherapy exposure (2022-03-29),

5. 11207409 - X-RAY psoralen activated cancer therapy (X-PACT) with associated treatments (2021-12-28),

6. 11135294 - Methods for radiotherapy to trigger light activation drugs (2021-10-05),

7. 10709900 - Phosphors and scintillators for light stimulation within a medium (2020-07-14),

8. 10596387 - Tumor imaging with X-rays and other high energy sources using as contrast agents photon-emitting phosphors having therapeutic properties (2020-03-24),

9. 10253367 - Biomarkers for locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC) (2019-04-09),

10. 10232190 - Phosphors and scintillators for light stimulation within a medium (2019-03-19),

11. 9907976 - Phosphors and scintillators for light stimulation within a medium (2018-03-06),

12. 9771620 - Biomarkers of high-grade serous ovarian carcinomas (2017-09-26),

13. 9709551 - Method for determining the sensitivity of an individual to low dose ionizing radiation (2017-07-18),

14. 9056080 - Use of an agent that restores tissue perfusion and oxygenation (2015-06-16),

15. 8968702 - Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses (2015-03-03),

Title: Mark W Dewhirst: A Pioneer in Therapeutic Innovations

Introduction: Mark W Dewhirst, a distinguished inventor based in Durham, NC (US), has made significant contributions to the field of medical advancements with his groundbreaking patented inventions. With a total of 16 patents to his name, Dewhirst continues to push the boundaries of innovation in the healthcare industry.

Latest Patents:

1. "Methods for radiotherapy to trigger light activation drugs": This patent introduces a method and system for treating subjects with disorders using photoactivatable drugs activated by Cherenkov radiation (CR) light.

2. "Tumor imaging with X-rays and other high energy sources using as contrast agents photon-emitting phosphors having therapeutic properties": This patent revolutionizes disease imaging and treatment by utilizing phosphors emitting ultraviolet or visible light for x-ray contrast and drug activation.

Career Highlights: Dewhirst's innovative work has been instrumental in advancing the fields of radiotherapy and disease imaging. He has worked with renowned institutions such as Duke University and Immunolight, LLC, showcasing his ability to translate cutting-edge research into practical applications.

Collaborations: Throughout his career, Dewhirst has collaborated with esteemed professionals in the industry, including Jonathan S Stamler and Pierre D Sonveaux. These collaborations have been essential in bringing his inventive ideas to life and driving progress in the medical field.

Conclusion: Mark W Dewhirst's exceptional ingenuity and relentless dedication to innovation have positioned him as a trailblazer in therapeutic inventions. His patented technologies continue to shape the future of healthcare, offering new possibilities for treating diseases and improving patient outcomes.